biostudies-literatureTaylor SACancer Research UKNational Institute for Health Research (NIHR)Wellcome Trust523-532https://www.ebi.ac.uk/biostudies/studies/S-EPMC6529610biostudies-literatureUnknown7(6)<h4>Background</h4>Whole-body magnetic resonance imaging (WB-MRI) could be an alternative to multi-modality staging of non-small-cell lung cancer (NSCLC), but its diagnostic accuracy, effect on staging times, number of tests needed, cost, and effect on treatment decisions are unknown. We aimed to prospectively compare the diagnostic accuracy and efficiency of WB-MRI-based staging pathways with standard pathways in NSCLC.<h4>Methods</h4>The Streamline L trial was a prospective, multicentre trial done in 16 hospitals in England. Eligible patients were 18 years or older, with newly diagnosed NSCLC that was potentially radically treatable on diagnostic chest CT (defined as stage IIIb or less). Exclusion criteria were severe systemic disease, pregnancy, contraindications to MRI, or histologies The Lancet. Respiratory medicineDiagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial.PMC652961013/122/01EME/13/122/0110/68/01NF-SI-0512-1001216463NF-SI-0513-10019ICA-CDRF-2017-03-053Naaseri SClarke CSMcKirdy FWin TWoodrow LPatel PSidhu HSPatel UCouture JPhiri PJenkins IGibbons NPrior KRoehrig JRussell PMohammed ABeeston TAdeniba RBeare SPrezzi DBlakeway LBirch DYu DPiga WJayme ANagy ZLauigan RConteh VHameeduddin ANichols PGreen ABridgewater JBazari FBeedham HHandousa MIlangovan ROnajobi AMorton AGreen EQuinn LStirling JHigginson AKellaway JRafiee HBlunt DKoh DMGoh VO'Connor SGlynne-Jones RDavis LEvans RBhowmik ABurke SDaniel ABorgstein RDavis AEllis SSrirajaskanthan RMarwood EReddi MGilbert KStreamline investigatorsCurry LDe Los JJanes SMRhodes ASimcock IBall SElton CSharp ALight TRamesh SMcCullogh JMorris SJohnson APardoe HKalasthry JKarp SJackson MObichere AO'Donohue JBharwani NO'Callaghan AChao DHoneyfield LLoke TKHanid GBalogun SWanstall CCollins CEkeowa UAtkin GStoycheva TSyeed FBhatnagar GLim LMallett SShahabuddin KTarver KOliver AWilson SCrosbie JAhmed SStegner SGourtsoyianni SBarhate KWilson JHurl LAlam AHughes LRaouf SJeyadevan NLucas NStrickland NHughes HHans BBeable RRienhardt AHans SAustria AMcGowan JThaha MASaull MBateman ANunes AWeir SRicketts WSargus KLock SDesai KVan Ree KLocke IDuggan MReczko KNawaz TShepherd BNavani NChang EDatt POlaleye ICurtis HShiu KKJohnston EWKay CKavidasan AHalligan STunariu NKarapanagiotou EChukundah Svan Someren CGogbashian ATaylor SAAmadi AVerjee AFerdous SO'Shaughnessy TLimbu PTrain MTeague JJalloh ALowe AEveritt CPartridge WMahmud SBreen DFurneaux MAnand GRahman FKelly-Morland CPadhani ARTulmuntaha SNtala EPrendergast CJulka PBoisfer DNorman CRich NLong MJannapureddy RWijeyekoon SScurr EButawan RGroves AMAgoramoorthy LCampbell YBoavida PRockall AGRobinson JSimeon CSmith DMills-Baldock TRiddle PPerry KSmith AEngledow AHadley EAboagye AMiles ASnell DHowling SPunwani SMaheswaran SMorgan VIsaac EKhan SfalseDiagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial.<h4>Background</h4>Whole-body magnetic resonance imaging (WB-MRI) could be an alternative to multi-modality staging of non-small-cell lung cancer (NSCLC), but its diagnostic accuracy, effect on staging times, number of tests needed, cost, and effect on treatment decisions are unknown. We aimed to prospectively compare the diagnostic accuracy and efficiency of WB-MRI-based staging pathways with standard pathways in NSCLC.<h4>Methods</h4>The Streamline L trial was a prospective, multicentre trial done in 16 hospitals in England. Eligible patients were 18 years or older, with newly diagnosed NSCLC that was potentially radically treatable on diagnostic chest CT (defined as stage IIIb or less). Exclusion criteria were severe systemic disease, pregnancy, contraindications to MRI, or histologies 2019-01-01T00:00:00Z2019 Jun2025-04-22T15:39:57.722Z2019-07-01T13:54:12ZS-EPMC65296103108012910.1016/S2213-2600(19)30090-6